Global Pulmonary Embolism Market – Industry Trends and Forecast to 2030

Análise e dimensão do mercado de embolia pulmonar

Nos últimos anos, prevê-se que o mercado global de embolia pulmonar cresça rapidamente durante o período de previsão 2023-2030. O mercado global de embolia pulmonar é impulsionado principalmente por um aumento na utilização da prevalência de doenças de embolia pulmonar. Nos idosos, as doenças pulmonares podem ser letais. Espera-se que a crescente prevalência deste problema de saúde entre a população idosa mundial impulsione as vendas do mercado global de embolia pulmonar nos próximos anos. Diferentes avanços tecnológicos estão a ser incorporados no setor da saúde em termos de diagnóstico, saúde e tratamento médico. Este cenário favorece a expansão do mercado global de embolia pulmonar.

A Data Bridge Market Research analisa que o mercado global de embolia pulmonar, que foi de 1,65 mil milhões de dólares em 2022, deverá atingir os 3,12 mil milhões de dólares até 2030, e deverá passar por um CAGR de 8,30% durante o período de previsão 2023-2030. Isto indica que o valor de mercado. A “dor no peito” domina o segmento de sintomas do mercado global de embolia pulmonar devido à crescente prevalência deste problema cardíaco entre a população idosa mundial. Além dos insights sobre cenários de mercado, tais como valor de mercado, taxa de crescimento, segmentação, cobertura geográfica e grandes players, os relatórios de mercado com curadoria da Data Bridge Market Research incluem também análise especializada aprofundada, epidemiologia de pacientes, análise de pipeline, análise de preços, e quadro regulamentar.

Âmbito e segmentação do mercado de embolia pulmonar

Definição de mercado

Uma embolia pulmonar é um coágulo sanguíneo no pulmão que se desenvolve quando um coágulo de outra região do corpo (geralmente a perna ou o braço) viaja através da corrente sanguínea e se aloja nas artérias sanguíneas do pulmão. Isto reduz o fluxo sanguíneo para os pulmões, reduz os níveis de oxigénio nos pulmões e aumenta a pressão arterial nas artérias pulmonares. Os EP podem causar danos cardíacos ou pulmonares, bem como morte, se não forem tratados imediatamente.  

Dinâmica global do mercado da embolia pulmonar

Motoristas

• Aumento da prevalência do cancro

O mercado global de embolia pulmonar é impulsionado por um aumento da prevalência do cancro. Os doentes que estão a receber quimioterapia ou que têm um historial familiar da doença correm maior risco, o que deverá aumentar a procura pelos medicamentos. Espera-se que a indústria se desenvolva em resposta ao crescente número de doentes oncológicos. O cancro matou cerca de 10 milhões de pessoas em 2020, segundo a Organização Mundial de Saúde.

• Aumentar o investimento em infraestruturas de saúde

Outro fator significativo que influencia a taxa de crescimento do mercado da embolia pulmonar é o aumento dos gastos em saúde que ajuda a melhorar as suas infraestruturas.

• Aumento do vício do tabagismo

O vício de fumar a longo prazo é uma das principais causas de doenças pulmonares, incluindo a embolia pulmonar. Os níveis de stress desta base populacional aumentaram significativamente como resultado da crescente urbanização, industrialização e aumento da pressão laboral. Espera-se que este cenário resulte num aumento do vício do tabagismo, o que levaria a um maior potencial de vendas no mercado mundial de embolia pulmonar.

Oportunidade

• Increase in the Number of Research and Development Activities

Moreover, the market's growth is fuelled by an increase in the number of research and development activities. This will provide beneficial opportunities for the global pulmonary embolism market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate. Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the global pulmonary embolism market growth during the forecast period 2023-2030.

Restraint/Challenge

• Limited Awareness and Knowledge

There is a lack of awareness and knowledge about pulmonary embolism among healthcare professionals and the general population. This can result in delayed recognition of symptoms, leading to delays in seeking medical attention and appropriate treatment.

This  global pulmonary embolism market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global pulmonary embolism market Contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In August 2021, Boston Scientific had announced the initiation of randomized controlled trial for the EkoSonic™ Endovascular System. In patients with PE and peripheral artery occlusions, the EKOS device employs ultrasound radiation in combination with a thrombolytic medication to break blood clots and restore blood flow. The EKOS system's ultrasound technology speeds up thrombolysis, or the breakup of a clot, reducing the time it takes to treat a patient and lowering the required thrombolytic dose, which can lead to better outcomes and a lower risk of bleeding.

Global Pulmonary Embolism Market Scope

The global pulmonary embolism market is segmented on the basis of symptoms, diagnosis, treatment, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

 Symptoms

• Shortness of Breath
• Chest Pain
• Cough
• Irregular Heartbeat
• Dizziness
• Fever
• Cyanosis
• Others

 Diagnosis

• Chest X-Ray
• ECG
• MRI
• CT Scan
• Pulmonary Angiography
• Venography
• Venous Ultrasound
• D-Dimer Test
• Others

Treatment

• Medications
• Mechanical Devices
• Surgery
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Global Pulmonary Embolism Market Regional Analysis/Insights

The global pulmonary embolism market is analysed and market size insights and trends are provided by country, product, application, type and end-users as referenced above.

The countries covered in the global pulmonary embolism market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the global pulmonary embolism market because of the presence of major key players and growing prevalence of pulmonary embolism diseases in this region.   

Asia-Pacific is expected to grow during the forecast period 2023-2030 due to rising number of geriatric people and increasing prevalence of pulmonary embolism in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure Growth Installed base and New Technology Penetration

 Global pulmonary embolism market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment’s, installed base of different kind of products for global pulmonary embolism market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the global pulmonary embolism market. The data is available for historic period 2015-2020.

Competitive Landscape and  Global Pulmonary Embolism Market Share Analysis

The global pulmonary embolism market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to pulmonary embolism market

Some of the major players operating in the global pulmonary embolism market are:

• Abbott (U.S.)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (U.S.)
• Teva Pharmaceutical Industries Ltd.(Jerusalem)
• Sanofi (France)
• Pfizer Inc. (U.S.)
• GlaxoSmithKline plc (U.K.)
• Bristol-Myers Squibb Company (U.S.)
• Hikma Pharmaceuticals PLC (U.K.)
• Johnson & Johnson Private Limited (U.S.)
• Novartis AG (Switzerland)
• Boehringer Ingelheim International GmbH. (Germany)
• Fresenius Kabi AG (Germany)
• Bayer AG (Germany)
• Eli Lilly and Company (U.S.)
• Merck & Co., Inc. (U.S.)
• Baxter (U.S.)
• AstraZeneca (U.K.)
• Genentech Inc. (U.S.)
• Aspen Holdings (South Africa)

SKU-55531